Literature DB >> 19442823

Intrathecal delivery of fluorescent labeled butyrylcholinesterase to the brains of butyrylcholinesterase knock-out mice: visualization and quantification of enzyme distribution in the brain.

Noel D Johnson1, Ellen G Duysen, Oksana Lockridge.   

Abstract

Exogenously delivered butyrylcholinesterase (BChE) has proven to be an efficient bioscavenger against highly toxic organophosphorus poisons and nerve agents. The scavenger properties of BChE when delivered via intramuscular, intravenous, subcutaneous, or intraperitoneal routes are limited to the body's peripheral sites because the 340 kDa enzyme does not cross the blood-brain barrier (BBB). Overcoming the BBB is an important step toward evaluating the neuroprotective properties of BChE within the central nervous system (CNS). This study examines the feasibility of delivering BChE to the brain and spinal cord by intrathecal (IT) injection. Mice completely devoid of BChE were injected intrathecally with either BChE (80 units) that was labeled with near-infrared fluorescent dye (BChE/IRDye) or a molar equivalent amount of carboxylate dye. The BChE/IRDye and carboxylate dye were tracked using an in vivo imaging system demonstrating the real-time distribution of BChE in the brain and the residence time in the brain and spinal cord through 25 h post-dosing. BChE/IRdye levels in the brain peaked at 6h post-dosing. BChE enzyme activity was quantified in plasma and brain sections by BChE activity assays of plasma and of perfused tissues. Average BChE activity levels were 0.6 units/g in the brains of mice treated with BChE/IRDye at 4h post-dosing. Intense fluorescent signal in the cortex, dentate gyrus and ventricles of the brain at 25 h post-dosing was visualized by confocal microscopy and the presence of BChE was confirmed with activity assays of frozen sections. This procedure proved to be an efficient, safe and rapid method to deliver BChE to the CNS of mice, providing a research tool for determining neural protection by BChE following OP exposure.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19442823      PMCID: PMC3864044          DOI: 10.1016/j.neuro.2009.03.001

Source DB:  PubMed          Journal:  Neurotoxicology        ISSN: 0161-813X            Impact factor:   4.294


  29 in total

1.  Hippocampal neurons express GABA A receptor insensitive to diazepam in hyperexcitable conditions.

Authors:  J Kapur
Journal:  Epilepsia       Date:  2000       Impact factor: 5.864

2.  Chronic neurological sequelae of acute organophosphate pesticide poisoning.

Authors:  E P Savage; T J Keefe; L M Mounce; R K Heaton; J A Lewis; P J Burcar
Journal:  Arch Environ Health       Date:  1988 Jan-Feb

Review 3.  Pharmacological effects of oximes: how relevant are they?

Authors:  H P van Helden; R W Busker; B P Melchers; P L Bruijnzeel
Journal:  Arch Toxicol       Date:  1996       Impact factor: 5.153

4.  Prevention of soman-induced cognitive deficits by pretreatment with human butyrylcholinesterase in rats.

Authors:  R Brandeis; L Raveh; J Grunwald; E Cohen; Y Ashani
Journal:  Pharmacol Biochem Behav       Date:  1993-12       Impact factor: 3.533

5.  Human butyrylcholinesterase as a general prophylactic antidote for nerve agent toxicity. In vitro and in vivo quantitative characterization.

Authors:  L Raveh; J Grunwald; D Marcus; Y Papier; E Cohen; Y Ashani
Journal:  Biochem Pharmacol       Date:  1993-06-22       Impact factor: 5.858

6.  Intrathecal enzyme replacement therapy reduces lysosomal storage in the brain and meninges of the canine model of MPS I.

Authors:  E Kakkis; M McEntee; C Vogler; S Le; B Levy; P Belichenko; W Mobley; P Dickson; S Hanson; M Passage
Journal:  Mol Genet Metab       Date:  2004 Sep-Oct       Impact factor: 4.797

7.  Protection by butyrylcholinesterase against organophosphorus poisoning in nonhuman primates.

Authors:  C A Broomfield; D M Maxwell; R P Solana; C A Castro; A V Finger; D E Lenz
Journal:  J Pharmacol Exp Ther       Date:  1991-11       Impact factor: 4.030

8.  Whole body and tissue imaging of the butyrylcholinesterase knockout mouse injected with near infrared dye labeled butyrylcholinesterase.

Authors:  Ellen G Duysen; Oksana Lockridge
Journal:  Chem Biol Interact       Date:  2008-03-07       Impact factor: 5.192

Review 9.  Review of oximes available for treatment of nerve agent poisoning.

Authors:  R M Dawson
Journal:  J Appl Toxicol       Date:  1994 Sep-Oct       Impact factor: 3.446

10.  Intrathecal morphine in mice: a new technique.

Authors:  J L Hylden; G L Wilcox
Journal:  Eur J Pharmacol       Date:  1980-10-17       Impact factor: 4.432

View more
  4 in total

1.  Quantum dot labeling of butyrylcholinesterase maintains substrate and inhibitor interactions and cell adherence features.

Authors:  Nir Waiskopf; Itzhak Shweky; Itai Lieberman; Uri Banin; Hermona Soreq
Journal:  ACS Chem Neurosci       Date:  2010-12-14       Impact factor: 4.418

2.  Biochemical characterization of fluorescent-labeled recombinant human alpha-L-iduronidase in vitro.

Authors:  Brigette L Tippin; Larisa Troitskaya; Shih-hsin Kan; Amanda K Todd; Steven Q Le; Patricia I Dickson
Journal:  Biotechnol Appl Biochem       Date:  2011-10-28       Impact factor: 2.431

3.  Visualization of exogenous delivery of nanoformulated butyrylcholinesterase to the central nervous system.

Authors:  Andrea Gaydess; Ellen Duysen; Yuan Li; Vladimir Gilman; Alexander Kabanov; Oksana Lockridge; Tatiana Bronich
Journal:  Chem Biol Interact       Date:  2010-01-11       Impact factor: 5.192

Review 4.  Pre-clinical whole-body fluorescence imaging: Review of instruments, methods and applications.

Authors:  Frederic Leblond; Scott C Davis; Pablo A Valdés; Brian W Pogue
Journal:  J Photochem Photobiol B       Date:  2009-11-26       Impact factor: 6.252

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.